Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1Dermatologic 1

Conditions

Lymphoma, Large-Cell, Anaplastic 2Lymphoma 2Dendritic Cell Sarcoma, Interdigitating 2Recurrence 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Hodgkin Disease 1

Interventions

Peripheral Blood Stem Cell Transplantation 41fludarabine phosphate 33Cyclophosphamide 31Mycophenolic Acid 25Whole-Body Irradiation 22Cyclosporine 22Busulfan 21Tacrolimus 20Antilymphocyte Serum 17Methotrexate 16Filgrastim 14Etoposide 12Radiotherapy 11Psychiatric Rehabilitation 11Melphalan 11Methylprednisolone 10Flow Cytometry 10Therapeutics 9Polymerase Chain Reaction 8Gemcitabine 8Rituximab 7sargramostim 6Vorinostat 6Sirolimus 6Cord Blood Stem Cell Transplantation 6Transplantation 5Nivolumab 5Dexamethasone 5Calcium Dobesilate 5Bortezomib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hodgkin Disease × iratumumab × Dermatologic × Clear all
NCT00059995 2013-05-30

MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
DermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡